"Long books, when read, are usually overpraised, because the reader wishes to convince others and himself that he has not wasted his time.” ? E.M. Forster, Aspects of the Novel
Iovance Biotherapeutics (IOVA) is one of several small biotech holdings making big moves this week for the Busted IPO Forum model portfolio. The company has received some new analyst commentary and, more importantly, posted some encouraging trial results. We take a look at both events and update on our investment thesis on this developmental concern in the paragraphs below.
Company Overview:
Iovance